CYDY CYTODYN INC
- 0.115000
- -0.003100-2.62%
CYTODYN INC News
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
Express News | Cytodyn Announces FDA Clearance of Its Phase II Oncology Trial
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies With SMC Laboratories
CYTODYN INC | 10-Q: Q1 2025 Earnings Report
Press Release: CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
Express News | Cytodyn Appoints DR. Max Lataillade as Senior Vice President and Head of Clinical Development
CytoDyn Announces Abstract That Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
CYTODYN INC | 10-K/A: Annual report (Amendment)
CytoDyn Announces Preliminary Findings in Study With SMC Laboratories
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Express News | Cytodyn Engages Leading Cro for Phase II Inflammation Trial
CYTODYN INC | 10-K: FY2024 Annual Report
Express News | Cytodyn Inc: Intends to Proceed With a Submission of Its Final Study Protocol to FDA
Express News | Cytodyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients With Relapsed/Refractory Microsatellite Stable Colorectal Cancer
Express News | Cytodyn Inc - Terms of Settlement Provide an Immediate Influx of Non-Dilutive Cash and Eliminates $14 Mln of Accounts Payable
Express News | Cytodyn Inc - Amarex to Pay Cytodyn $12 Million
Express News | Cytodyn Announces Settlement With Amarex Clinical Research LLC
FDA Lifts Clinical Hold on CytoDyn Drug, Stock Rallies 22%
Express News | CytoDyn Announces Submission Of Clinical Protocol To FDA And Initiation Of Pre-Clinical Study In Glioblastoma
Express News | CytoDyn Appoints Jacob Lalezari As CEO, Effective Jan. 26, 2024; Mitchell Cohen Appointed Interim CFO, Effective Feb. 1, 2024
Analysis
Price Target
No Data
No Data